medigraphic.com

2017, Number 2

<< Back Next >>

Rev Mex Anest 2017; 40 (2)

Comparison of two halogenated in patients undergoing kidney transplantation

Fernández-García JO, Hernández-Caballero K, Vásquez-Márquez PI, Villegas-Anzo F, Zarazúa-Juárez M, Castellanos-Olivares A

Language: Spanish
References: 19
Page: 79-83
PDF size: 217.01 Kb.


ABSTRACT

Introduction: Renal transplantation is a high-risk procedure, so integral cardiac monitoring is essential. Objective: To compare cardiac output (CO), cardiac index (CI), serum levels of brain natriuretic peptide (BNP), central venous pressure (CVP) and urinary volumes with the use of two inhaled anesthetic agents in the context of renal transplantation. Material and methods: A controlled clinical trial was conducted; 42 patients undergoing kidney transplantation were studied. Two groups of 21 patients were formed each: group I received isoflurane and group D received desflurane. Results: The groups were similar in their general characteristics. Compared to BNP, the difference in T3 was 274.10 pg/mL ± 152.95 vs. 371.57 pg/mL ± 146.64 (p =0.041) and T5 250.48 pg/mL ± 218.58 vs. 378.67 pg/mL ± 129.39 (p = 0.026) for group I and group D respectively. The following differences were observed in relation to CO and CI: CO in T3 8.47 ± 2.86 L/min vs. 11.43 ± 3.13 L/min (p = 0.003), CI in T3 5.24 ± 1.70 L/min/m2 vs. 6.86 ± 1.85 L/min/m2 (p = 0.005) for group I and group D respectively. In relation to CVP, there were differences in T2 14.43 ± 5.10 cmH2O vs. 18.52 ± 3.40 cmH2O (p = 0.004), in T3 12.67 ± 4.46 cmH2O vs. 18.29 ± 4.55 cmH2O (p = 0.000), in T4 11.43 ± 3.62 cmH2O vs. 15.71 ± 5.11 cmH2O (p = 0.003) and in T5 10.67 ± 4.93 cmH2O vs. 15.52 ± 5.65 cmH2O (p = 0.005) for group I and group D respectively. Urinary rates had the following differences: 5.91 ± 2.28 mL/kg/h vs. 3.01 ± 2.33 mL/kg/h (p = 0.000) for group I and group D respectively. Conclusion: BNP levels and hemodynamic variations were lower with isoflurane use. Urinary rates were higher with isoflurane use.


REFERENCES

  1. CENATRA. Estado actual de donación y trasplantes en México. 2011;12-26.

  2. Lemmens HJ. Kidney transplantation: recent developments and recommendations for anesthetic management. Anesthesiol Clin North America. 2004;22:651-662.

  3. Drury N. Anaesthesia for renal transplantation. ATOTW. 2010;174:1-6.

  4. Sood J, Vohra V. Anesthesia for trasplant surgery. Chapter 7. India: Jaypee Brothers Medical Publishers; 2014. pp. 125-143.

  5. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.

  6. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992;86:1081-1088.

  7. Chen WC, Tran KD, Maisel AS. Biomarkers in heart failure. Heart. 2010;96:314-320.

  8. Takase H, Dohi Y. Kidney function crucially affects BNP, NT-proBNP and their relationship. Eur J Clin Invest. 2014;44:303-308.

  9. Hogenhuis J, Voors AA, Jaarsma T, Hoes AW, Hillege HL, Kragten JA, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail. 2007;9:787-794.

  10. Umbrain V, Keeris J, D’Haese J, Verborgh C, Debing E, Van den Brande P, et al. Isoflurane, desflurane and sevoflurane for carotid endarterectomy. Anaesthesia. 2000;55:1052-1057.

  11. Tritapepe L, Landoni G, Guarracino F, Pompei F, Crivellari M, Maselli D, et al. Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Eur J Anaesthesiol. 2007;24:323-331.

  12. Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, Menasché P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation. 1999;100:II340-II344.

  13. Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003;123:1577-1582.

  14. Litz RJ, Hübler M, Lorenz W, Meier VK, Albrecht DM. Renal responses to desflurane and isoflurane in patients with renal insufficiency. Anesthesiology. 2002;97:1133-1136.

  15. Osca J, Quesada A, Arnau MA, Osa A, Hervás I, Almenar L, et al. Péptido cerebral natriurético. Valor diagnóstico en la insuficiencia cardíaca. Rev Esp Cardiol. 2002;55:7-15.

  16. Egleé E, Gómez B. Péptido natriurético cerebral en pacientes con insuficiencia cardíaca o con factores de riesgo para su desarrollo. Insuf Card. 2008;3:21-27.

  17. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.

  18. Smith CE, Hunter JM. Anesthesia for renal transplantation: relaxants and volatiles. Int Anesthesiol Clin 1995; 33:69-92.

  19. Masuo K, Rakugi H, Ogihara T, Esler MD, Lambert GW. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev. 2010;6:58-67.




2020     |     www.medigraphic.com